Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection
1. TVGN 116's rNPV exceeds $325 million for U.S. market. 2. 5-year revenue forecast for TVGN 116 estimated at $6.5 billion. 3. Tevogen claims unique drug development model for sustainability. 4. Progress on TVGN 489 supports rapid milestone achievements. 5. Forward-looking statements address various operational risks.